Hancock Jaffe Gears Up for Pivotal Trial to Treat Chronic Venous Insufficiency

Hancock Jaffe Laboratories has raised $41 million in a public offering to fund a pivotal trial for its VenoValve device. The Irvine, CA-based company’s VenoValve is a porcine-based device for the treatment of lower limb Chronic Venous Insufficiency (CVI) of the deep vein system.